检索临床试验

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. 本研究的目的是评价最佳剂量, 不良事件, livmonplimab联合budigalimab的疗效观察.

Livmoniplimab是一种正在开发用于治疗HCC的研究药物. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), lenvatinib, 或索拉非尼. Approximately 120 adult participants will be enrolled in the study across 60 sites worldwide.

第1组(对照组), participants will receive the investigator's choice: lenvatinib as an oral capsule 或索拉非尼 as an oral tablet, 每天一次. 在手臂2中, participants will receive intravenously (IV) infused livmoniplimab (dose A) in combination with IV infused budigalimab, 每3周. 在手臂3, participants will receive intravenously (IV) infused livmoniplimab (dose B) in combination with IV infused budigalimab, 每3周. 预计研究时间长达2年

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, 血液测试, 调查问卷, 并扫描.

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1311在晚期实体瘤患者中的安全性和耐受性.

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, 法尼基转移酶抑制剂(FTI), 作为单一疗法和联合疗法, 成年晚期实体瘤患者.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, TORL-4-500在晚期肿瘤患者中的抗肿瘤活性

本研究的目的是评估替拉古单抗的有效性和安全性, 抗tigit单克隆抗体, when administered in combination with atezolizumab and bevacizumab as first-line treatment, 在不可切除的参与者中, 局部晚期或转移性肝细胞癌.

这是1/2阶段, 多中心, 非盲 (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, TORL-3-600在晚期肿瘤患者中的抗肿瘤活性

这项研究是开放标签的, 第一阶段, 多中心研究评价安全性, 耐受性, 药物动力学(PK), 一种新型片段结晶化(Fc)工程免疫球蛋白G1抗细胞毒性t淋巴细胞抗原4(抗ctla -4)人单克隆抗体(botensilimab)单药治疗和与抗程序性细胞死亡蛋白1 (PD-1)抗体(balstilimab)联合使用的药效学(PD)谱, and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy and in combination with balstilimab.

The main purpose of the study is to evaluate the safety and 耐受性 of HRO761 and identify the recommended dose(s), i.e., HRO761单独或联合替利单抗或伊立替康的最佳安全和有效剂量，可以给予患有称为MSIhi(微卫星不稳定性高)或dMMR(错配修复缺陷)的特定分子改变的癌症患者，这可能最有效地治疗这些特定的癌症类型，并了解HRO761治疗这些癌症的效果.

这项临床试验的目的是测试CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

它旨在回答的主要问题是:

• 评估CPO301增加剂量的安全性和耐受性，并确定研究第二部分(A部分)的使用剂量。
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• 评估CPO301被人体代谢的速度(药代动力学或PK)
• 评估研究药物是否产生抗体(免疫原性)
• 评价药物的初步疗效
• 将初步疗效与一种叫做EGFR的生物标志物的突变联系起来

参与者将:

• 提供书面知情同意
• 进行筛选测试以确保他们有资格接受研究治疗
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, 基于参与者在治疗中的表现
• 每3个月随访一次病情进展，持续2年

这是Ib/II期, 非盲, 多中心, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, 或者修改参与者群体.

这项研究正在研究一种新的化合物, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

这项研究的目的是观察这种药物是否, abemaciclib, 与其他药物一起使用杀死癌细胞是否安全有效. 该研究对患有实体瘤的儿童和年轻人开放, 包括神经母细胞瘤, 在其他抗癌治疗中没有反应或增长. 对每个参与者来说，这项研究预计将持续2年.

本研究的目的是确定amivantabab和capmatinib联合治疗1期非小细胞肺癌(NSCLC)患者的推荐2期联合剂量(RP2CD[s])(联合剂量选择)。, 并评估阿米万他单和卡马替尼联合治疗间充质上皮转化(MET)外显子14跳变突变和MET扩增的NSCLC的抗肿瘤效果, 在第2阶段(扩展)中选定的RP2CD进行管理时.

该研究尚未在ClinicalTrials上注册.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• 如果您需要临床试验方面的帮助.注册肿瘤学研究，请联系 Jonsson综合癌症中心的法规遵从办公室.
• 如果您需要临床试验方面的帮助.非肿瘤学研究的注册，请联系 监管事务办公室.

本研究的主要目的是评估E7386的安全性和耐受性，并确定E7386与其他抗癌药物联合的推荐2期剂量(RP2D)。.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. 本研究的目的是评估ABBV-400用于治疗晚期实体瘤时的不良事件和疾病活动度的变化.

ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. 研究医生将参与者分成治疗组. 将探讨推荐的2期剂量(RP2D). 每个治疗组接受不同剂量的ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with bevacizumab. 大约500名患有NSCLC的成年参与者, gastroesophageal adenocarcinoma/gastroesophagel junction adenocarcinoma (GEA) and colorectal cancer (CRC) or advanced solid tumors, 将在全球范围内约7-10个剂量递增阶段的地点和85-95个剂量扩展阶段的地点纳入研究.

剂量递增武器, 参与者将接受静脉(IV)递增剂量的ABBV-400单药治疗. 剂量膨胀臂, 以下晚期实体瘤适应症的参与者:egfr表达野生型非鳞状NSCLC (wtEGFR NSCLC) [Part 2i]或egfr表达突变(mutEGFR NSCLC) [Part 2ii], 鳞状非小细胞肺癌[第2iii部分], GEA [Part 3]将接受静脉(IV) ABBV-400单药治疗, CRC参与者将扩大接受IV ABBV-400单药治疗[Part 4], participants MET amplification will receive IV ABBV-400 monotherapy in expansion [Part 5], MET突变参与者将扩大接受IV ABBV-400单药治疗[Part 6], participants CRC safety lead in will receive escalating doses of IV ABBV-400 in combination with IV bevacizumab [Part 7a], 第7a部分确定的IV ABBV-400与IV贝伐单抗或口服trifluridine/tipiracil (TAS-102)片联合使用的低剂量或高剂量[第7b部分].

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). 医疗评估将经常检查治疗效果, 血液测试, 问卷调查和副作用.